Survivin contributes to DNA repair by homologous recombination in breast cancer cells

Breast Cancer Research and Treatment

Volumn 155, Issue 1, 2016, Pages 53-63

  Véquaud, Eloïse ^a   Desplanques, Grégoire ^a   Jézéquel, Pascal ^a,b   Juin, Philippe ^a,b   Barillé Nion, Sophie ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b Institut de Cancé Rologie de L'Ouest ICO   (France)

Author keywords

Breast cancer; DNA damage; Homologous recombination; Survivin

Indexed keywords

AURORA B KINASE; BLOOM SYNDROME HELICASE; CELL CYCLE PROTEIN 20; ENDONUCLEASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN EME1; PROTEIN MUS8; PROTEIN P53; RAD51 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; CDC20 PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; INHIBITOR OF APOPTOSIS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; BLM GENE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EME1 GENE; ENZYME INHIBITION; EXO1 GENE; GENE; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAD51 GENE; SURVIVIN GENE; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE SILENCING; GENETICS; METABOLISM; PROGNOSIS; TUMOR CELL LINE;

AURORA KINASE B; BREAST NEOPLASMS; CDC20 PROTEINS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HISTONES; HOMOLOGOUS RECOMBINATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84953356156     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3657-z     Document Type: Article

References (40)

1. Altieri DC (2008) New wirings in the Survivin networks. Oncogene 27:6276–6284
2. Ruchaud S, Carmena M, Earnshaw WC (2007) Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 8:798–812
3. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22:2934–2947
4. Dohi T, Xia F, Altieri DC (2007) Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 27:17–28
5. Song Z, Yao X, Wu M (2003) Direct interaction between Survivin and Smac/DIABLO is essential for the anti-apoptotic activity of Survivin during taxol-induced apoptosis. J Biol Chem 278:23130–23140
6. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70
7. Brennan DJ, Rexhepaj E, O’Brien SL, McSherry E, O’Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM (2008) Altered cytoplasmic-to-nuclear ratio of Survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14:2681–2689
8. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 35:2817–2826
9. Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, Lasla H, Guette C, Valo I, Verrièle V, Campone M (2015) Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res 17:43
10. Lee CW, Raskett CM, Prudovsky I, Altieri DC (2008) Molecular dependence of estrogen receptor-negative breast cancer on a notch-Survivin signaling axis. Cancer Res 68:5273–5281
11. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC, Finkel T, Deng CX (2008) Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32:11–20
12. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J (2004) Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23:7494–7506
13. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D (2009) Mitotic deregulation by Survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 15:1326–1334
14. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y (2008) gammaH2AX and cancer. Nat Rev Cancer 8:957–967
15. Krejci L, Altmannova V, Spirek M, Zhao X (2012) Homologous recombination and its regulation. Nucleic Acids Res 40:5795–5818
16. Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F (2009) Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res 29:223–228
17. Reichert S, Rödel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, Kaina B, Rödel F (2011) Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 101:51–58
18. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819
19. Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barillé-Nion S (2014) Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis 5:e1291
20. Nelson G, Buhmann M, von Zglinicki T (2009) DNA damage foci in mitosis are devoid of 53BP1. Cell Cycle 8(20):3379–3383
21. Laulier C, Barascu A, Guirouilh-Barbat J, Pennarun G, Le Chalony C, Chevalier F, Palierne G, Bertrand P, Verbavatz JM, Lopez BS (2011) Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res 71:3590–3602
22. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, Davodeau F, Cherel M (2005) Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 11:7047s–7052s
23. Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, Campone M (2013) bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford) bas060
24. Jézéquel P, Campone M, Gouraud W, Charbonnel C, Leux C, Ricolleau G, Campion L (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131:765–775
25. Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee MC, Guan A, Hesley JA, Miller SC, Cromwell EF, Solow-Cordero DE, Meyer T, Cimprich KA (2009) A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell 35:228–239
26. Minocherhomji S, Hickson ID (2014) Structure-specific endonucleases: guardians of fragile site stability. Trends Cell Biol 24:321–327
27. Laguette N, Brégnard C, Hue P, Basbous J, Yatim A, Larroque M, Kirchhoff F, Constantinou A, Sobhian B, Benkirane M (2014) Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156:134–145
28. Naim V, Wilhelm T, Debatisse M, Rosselli F (2013) ERCC1 and MUS81-EME1 promote sister chromatid separation by processing late replication intermediates at common fragile sites during mitosis. Nat Cell Biol 15:1008–1015
29. Kostrouchova M, Kostrouch Z, Saudek V, Piatigorsky J, Rall JE (2003) BIR-1, a Caenorhabditis elegans homologue of Survivin, regulates transcription and development. Proc Natl Acad Sci USA 100:5240–5245
30. Wang F, Dai J, Daum JR, Niedzialkowska E, Banerjee B, Stukenberg PT, Gorbsky GJ, Higgins JM (2010) Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science 330:231–235
31. Tang L, Ling X, Liu W, Das GM, Li F (2012) Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by Survivin is at least partially p53-dependent: evidence for Survivin acting as a transcription factor or co-factor. Biochem Biophys Res Commun 421:249–254
32. Li Y, Ma X, Wu X, Liu X, Liu L (2014) Prognostic significance of survivin in breast cancer: meta-analysis. Breast J 20(5):514–524
33. Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S (2014) Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res 16(3):R55
34. Hu Y, Xu K, Yagüe E (2015) miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat 151(2):269–280
35. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F (2003) Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55:1341–1347
36. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J et al (2004) Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64:2840–2845
37. Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G, Krämer OH (2014) Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta 1845:202–220
38. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F (2012) A novel small molecule FL118 that selectively inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One 7:e45571
39. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K (2008) Radiosensitizing effect of YM155, a novel small-molecule Survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 14:6496–6504
40. Véquaud E, Séveno C, Loussouarn D, Engelhart L, Campone M, Juin P, Barillé-Nion S (2015) YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network. Oncotarget 6(15):13476–13486